AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04825847 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS monitor
Description: Information provided by the BIS (Medtronic, Canada) monitor will guide the volatile anesthetic administration in the EEG-guided group to maintain a BIS value between 40 and 60, a Suppression Ratio (SR; % of time with suppressed brain electrical activity) at 0% or the closest, a direct EEG display without any suppression time and a spectrogram (DSA or density spectral array) with most of the EEG wave frequency within the Alpha (8-12Hz), Theta (4-8Hz) and Delta (0.5-4Hz) frequencies.
Study NCT04825847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In the standard care group, the age-adjusted Minimum Alveolar Concentration (MAC-age) of sevoflurane will be kept at \[0.8-1.2\] MAC.
Study NCT05360394 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Coated Balloon
Description: CAS treated with PCB only
Study NCT05360394 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Coated Balloon and Stent Graft
Description: CAS treated with PCB first before deployment of stent graft
Study NCT05376553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100mg/m² intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline~Schedule: Day 1, every 21 days (+ 2 days)
Study NCT06514651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
Study NCT06559605 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: zirconia barrier
Description: barrier membrane used for guided bone regeneration and augmentation of ridge defect
Study NCT06559605 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: titanium mesh
Description: barrier membrane used for guided bone regeneration
Study NCT05970289 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-IFNα
Description: PEG-IFNα will be given via subcutaneous injection
Study NCT05970289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRII-835
Description: BRII-835 will be given via subcutaneous injection
Study NCT05376553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/2 intravenous infusion over 60 minutes, mixed as described in~Schedule: Day 1, every 21days (+ 2 days)
Study NCT05349370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isotopically labeled lactate
Description: A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn
Study NCT02454764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + Interferon alpha 2b
Study NCT02454764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil Fumarate
Study NCT04644757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Listening
Description: The study will employ an individual receptive relaxation music method with participants selecting music based on their preference from a selection of various styles from the MUSIC CARE© app. The music intervention will last 20 minutes per session and will be administered twice daily for 4 consecutive days. Participants will be given an electronic tablet with the MUSIC CARE© app loaded on it and trained on how to access the app to select their preferred style of music.Participants will be instructed to use the provided headphone during all interventions and to sit in a quiet area while wearing an ocular mask to avoid distractions.The PI will remotely monitor each of the music intervention sessions in real-time monitoring via a secured video conferencing interface to ensure adherence to study protocol.
Study NCT06426225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: General Anesthesia Applied Group 2 Patients.
Study NCT06426225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Aneshtesia
Description: Spinal Anesthesia and Ketofol Sedation Applied Group 1 Patients.
Study NCT05069688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Patients will receive standard TB and HIV treatment, however, for two weeks (study weeks 20-21) the dose of rifampicin will be increased from standard-dose to high-dose to assess pharmacokinetics and safety
Study NCT06561607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for Injection
Description: TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
Study NCT06561607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
Description: Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment.~* Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle.~* Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly.~* Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle.
Study NCT06562400 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Palmitoyl ethanolamide
Description: PEA supplementation (600mg twice a day for three months)
Study NCT06562400 — intervention group
Intervention type: BEHAVIORAL
Intervention: Ketogenic diet
Description: Diet characterized by the following percentages of macronutrients: 65% fat, 27% protein and 8% carbohydrates
Study NCT06467513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine hydrochloride injection
Description: The low dose esketamine hydrochloride group was given 0.2mg/kg at induction of anesthesia, the high dose esketamine hydrochloride group was given 0.4mg/kg at induction of anesthesia, and the blank control group was not given Esketamine hydrochloride injection at induction of anesthesia.
Study NCT06314035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD Patient Decision Aid
Description: Participants in this group will receive two 60-minute intervention sessions in one month. The COPD PDA consists of three main parts: The first component, clinical counselling, guides the participants in reviewing the common EOL scenarios. The second component, an evidence-based decision aid, is presented as an option grid in a booklet and a video to provide information about outcome probabilities of various treatment options and survival estimates in a balanced and unbiased manner. The information is presented in plain language for laypersons. The third component, decision coaching, introduces the concept of ACP and guides deliberation through value clarification.
Study NCT06314035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General Health Coaching Intervention
Description: The participants in the control group will receive two 60-minute health coaching sessions developed by the PI for another project as an attention placebo control. Trained research personnel will use the same amount of interaction time and similar formats to avoid threats to the study's internal validity. This intervention will focus on lifestyle modification and self-care management unrelated to the tested intervention content or outcomes. The trained research personnel will give the guidebook consisting of general self-management advice to participants in this group.
Study NCT05540691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear noise-cancelling earphones
Description: Intervention of wearing noise-canceling earphones after general anesthesia
Study NCT06264934 — intervention group
Intervention type: DEVICE
Intervention: Breast scan using the Z-scanner
Description: Four repeated scans of both breasts using the Z-scanner.
Study NCT06264934 — intervention group
Intervention type: DEVICE
Intervention: Breast scan using the Z-scanner
Description: A scan of both breasts using the Z-scanner.
Study NCT05896995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Exercise
Description: Pilates exercises target the deep muscles of the core, including the abdomen, lower back, hips, and glutes, while also engaging the whole body.
Study NCT05896995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mckenzie Exercise
Description: The McKenzie Method emphasizes self-treatment and active patient involvement in the management of their condition. It involves a systematic assessment process to determine the most appropriate exercises and interventions for an individual based on their specific symptoms and movement responses.
Study NCT05592574 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood samples required to performe IL-17 Dosage
Study NCT06126744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVR-C5252
Description: MVR-C5252 is a genetically modified next generation oncolytic herpes simplex virus 1 (oHSV1) with an active domain of human IL-12 and Fab fragment of anti-PD-1 antibody. This is a Phase 1 open label study designed to determine the safety and tolerability of MVR-C5252. The dose-escalation portion of the study will be conducted in 4 stages to evaluate the safety of infusion and determination of the MTD/RP2D followed by efficacy assessment.
Study NCT04507854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength, range of motion and functional tests + Questionnaire
Description: Patients undergoing instability surgery will perform amplitude, strength, functional tests and a questionnaire at 6 months of the operation. Then they will be contacted at 12, 18 and 24 months to find out if they have regained their performance level or if they have injured their shoulder again.
Study NCT05067998 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: IV Vitamin Infused Therapy Treatment
Description: Vitamin B, C, D, E, K, liquid vitamins, antioxidants, amino acids, and minerals
Study NCT05067998 — intervention group
Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine is the use of plants to treat disease and enhance general health and wellbeing. Examples of common herbal health products and supplements include black cohosh, echinacea, garlic, ginkgo, saw palmetto, and St. John's wort just to name a few.
Study NCT05414253 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Parallel Assignment
Description: Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
Study NCT05414253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parallel Assignment
Description: Single-centre randomized, parallel design, clinical trial with a 2 week follow-up
Study NCT04748991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant
Description: Post operative AF after cardiac surgery. Vernakalant 3mg/kg over 10 minutes followed by 2mg/kg over 10 minutes if still in AF.
Study NCT04748991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Post operative AF after cardiac surgery. Amiodarone 150mg IV followed by 1 mg/min x 6 hours then 0.5 mg/min x 12 hours
Study NCT05025527 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: biparametric MRI (bpMRI)
Description: Men go for the bpMRI for PCa (prostate cancer) screening, those who had a suspicious result will go for the next confirmation test
Study NCT05025527 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Prostate cancer antigen (PSA)
Description: Men go for the PSA test for PCa screening, those who had a suspicious result will go for the next confirmation test
Study NCT01661647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D knee kinematic assessment under local anesthesia
Description: 3D knee kinematic assessment under local anesthesia
Study NCT05131971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3888130B
Description: GSK3888130B will be administered.
Study NCT05131971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered.
Study NCT06243926 — intervention group
Intervention type: OTHER
Intervention: Sperm selection for ICSI
Description: Sperm selection for ICSI is a critical step to ensure the use of viable and healthy sperm for fertilization in vitro. The goal is to choose a sperm that has the best chance of resulting in a successful pregnancy.
Study NCT06500221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentive spirometry
Description: The incentive spirometer is widely used in physical, speech, and respiratory therapy, as well as in preventing postoperative pulmonary infections and improving sputum clearance. Consequently, this study aims to further confirm the role and effectiveness of incentive spirometry in improving lung function, activity endurance, and long-term blood sugar and lipid indices in patients with Type 2 diabetes combined with sarcopenia.
Study NCT06253429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioctic Acid 333 MG Oral Capsule
Description: Antioxidant compound which serve as a cofactor for mitochondrial respiratory enzymes
Study NCT06253429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Captopril 25Mg Tab
Description: Oral angiotensin-converting enzyme inhibitors
Study NCT06253429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Captopril 25Mg Tab
Description: Oral angiotensin-converting enzyme inhibitors
Study NCT04985656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat IV infusion
Study NCT04985656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine tablets
Study NCT04985656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cedazuridine
Description: Cedazuridine tablets
Study NCT05450718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine-naloxone
Description: Low-dose initiation of buprenorphine-naloxone protocol
Study NCT05450718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine-naloxone
Description: Standard clinical guidelines for a two-day buprenorphine-naloxone initiation
Study NCT05333744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
Study NCT05333744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone po, 20mg per day for 2 weeks, if response (Plt 30-100×100\^g/L),gradually taper to the maintenance dose（5-10mg per day）until 6 weeks after delivery; if not response, gradually taper to withdrawal.
Study NCT05333744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human TPO
Description: rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
Study NCT05666856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement And Family Training
Description: Community Reinforcement Approach and Family Training (CRAFT) is a scientifically based intervention designed to help concerned significant others (CSOs) to engage treatment-refusing substance abusers into treatment. This new intervention method was developed with the belief that the CSO can play a powerful role in helping to engage the substance user in treatment. It is often the substance user who reports that family pressure or influence is the reason sought treatment. CSOs benefit by becoming more independent and reducing their depression, anxiety and anger symptoms even if their loved one does not enter treatment.~CRAFT uses a positive approach versus confrontation, emphasizing learning new skills to cope with old problems. Some components include: how to stay safe, outlining the context in which substance abusing behavior occurs, teaching CSOs how to use positive reinforcers (rewards) and how to let the substance user suffer the natural consequences for their using behavior.
Study NCT05666856 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: We The Village Peer Community Forum
Description: An online peer support forum with other CSOs. Members of the forum post questions or comments to weekly peer-led discussions and receive responses and feedback from other CSO forum members. Members typically express concerns regarding their IP's wellbeing and ask other members to share any strategies they have employed when dealing with their IPs. Interactions typically, are based either in 12-Step strategies members have learned (usually through Al-Anon or Nar-Anon Family Groups or Family Training Workshops provided by treatment programs) or in CRAFT skills learned (usually from treatment programs or other We The Village members). A staff member from We The Village monitors forum interactions to ensure members are interacting respectfully.
Study NCT05776602 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fast MRI (Neuromix)
Description: Diagnostic performance, correlation, agreement
Study NCT05106790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational support with peer counseling
Description: This group will receive peer counseling therapy sessions will be led by doctors who specialize in hypertension. Patients and their families will be the focus of the sessions. Face-to-face sessions will take roughly 25-30 minutes. Patients will receive spoken and written instructions based on their abilities during these sessions. The counseling sessions are geared toward overcoming both general and personal obstacles. The educational component will be delivered through smart booklets. Information on hypertension, blood pressure self-monitoring, and frequent systolic blood pressure (SBP) tests, as well as body weight and serum cholesterol values, are included in the instructional support. Food control, exercise therapy, and hypertension problems and their management will also be explored as non-pharmacological therapeutic approaches.
Study NCT05106790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth intervention
Description: This group will receive mHealth intervention will include daily written and voice messages, and once weekly an educational-led video. This intervention module will be delivered through WhatsApp.
Study NCT05106790 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: mHealth intervention and Educational support with peer counseling
Description: This group will receive both Educational support (Smart booklets) with peer counseling sessions on a monthly basis and mHealth intervention will include daily written and voice reminders, and once weekly an educational led video.
Study NCT04819620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN-232
Description: Active Drug
Study NCT04819620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT04800666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
Study NCT04800666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Facial Nerve Block
Description: Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )
Study NCT04800666 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8
Study NCT04800666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecobalamin Tablets
Description: oral Mecobalamin Tablets tid-8
Study NCT06006221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qi-gong relaxation exercise
Description: Qi-gong relaxation exercise is a mindfulness-based exercise and is a type of exercise that consists of breathing-compatible body movements and relaxation used to relax the body and mind, reduce stress, distract attention from negative thoughts, accelerate blood flow, and improve emotions.
Study NCT04919551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vicagrel
Description: Oral administration after fasting/high-fat meal/low-fat meal
Study NCT04621786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD - ECT Multi-Channel Stimulation Interface
Description: The Mecta Spectrum 5000Q paired with Soterix Medical 4X1 HD-ECT Multi-Channel Stimulation Interface will reduce ECT current amplitude for amplitude-seizure titration.
Study NCT05257161 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Emboshield NAV6™
Description: Embolic Protection System for Carotid Artery Revascularization ( distal - filter) + stent CGuardTM™